The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 200
Summary
- Conditions
- Breast Neoplasms
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 50 years and 69 years
- Gender
- Only males
Description
This study's primary aim is to determine rates of recurrence with the innovative approach of considering tumor biology to select patients who may avoid radiation, with restriction of eligibility to women aged 50-69 with hormone-sensitive, Her2-negative tumors with Oncotype-DX RS ? 18 who plan to rec...
This study's primary aim is to determine rates of recurrence with the innovative approach of considering tumor biology to select patients who may avoid radiation, with restriction of eligibility to women aged 50-69 with hormone-sensitive, Her2-negative tumors with Oncotype-DX RS ? 18 who plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at low risk of LRR in whom omission of adjuvant radiation is reasonable.
Tracking Information
- NCT #
- NCT02400190
- Collaborators
- University of Pennsylvania
- Rutgers Cancer Institute of New Jersey
- East Carolina University
- Stanford University
- Harvard University
- Yale University
- Medical College of Wisconsin
- Memorial Sloan Kettering Cancer Center
- University of Texas Southwestern Medical Center
- Johns Hopkins University
- Loyola University
- Investigators
- Principal Investigator: Reshma Jagsi, M.D., Ph.D. University of Michigan
Get Well Soon